The Proteogenomics of Prostate Cancer Radioresistance

Prostate cancer is the second most common cause of cancer death in men, and radiotherapy is a standard curative therapy for it. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic and proteomic data to characterize the determinants of prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy.We deposited genomic and transcriptomic data of two types of radioresistant cell lines, DU145 and 22Rv1, and their corresponding parental (control) samples.